- Home
- PBA vs ROIV Comparison
PBA vs ROIV Comparison
Compare PBA & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBA | ROIV |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | Canada | United Kingdom |
| Employees | 2997 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4B | 20.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PBA | ROIV |
|---|---|---|
| Price | $44.45 | $29.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.56 |
| AVG Volume (30 Days) | 1.3M | ★ 5.9M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 4.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,053,000.00 |
| Revenue This Year | $7.38 | N/A |
| Revenue Next Year | $6.00 | $385.85 |
| P/E Ratio | $21.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.13 | $8.73 |
| 52 Week High | $45.09 | $30.03 |
Technical Indicators
Market Signals| Indicator | PBA | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 62.86 | 66.48 |
| Support Level | $36.50 | $20.46 |
| Resistance Level | $44.85 | N/A |
| Average True Range (ATR) | 0.83 | 0.96 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 79.07 | 84.62 |
Price Performance
Historical ComparisonAbout PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports. It also has a joint venture through the Cedar LNG export terminal.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.